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In this randomized prospective trial, Dr Angiletta and colleagues
have shown that perioperativeDexamethasone (DEX) administration
reduces the incidence of clinically apparent, temporary, carotid end-
arterectomy (CEA) associated cranial nerve (CN) dysfunction from
5.7% to 2.3% (P  .009). This benefit was achieved with no adverse
effects attributable to the steroid. Interestingly, DEX administration
had no effect on the incidence of permanent CN dysfunction in this
study. The authors’conclusion that temporary CN dysfunction is
often related to operative trauma induced perineural inflammation,
which is mitigated by DEX treatment, is both novel and plausible.
ThatDEX administration has no effect on the incidence of permanent
CN dysfunction suggests that such injuries are the result of direct
nerve trauma (transection or crush) not ameliorated by steroid pre-
treatment.
Two questions regarding the role of steroids in cranial nerve
dysfunction remain unanswered by this study. First, in formulating
their hypothesis and experimental design, the authors were influ-
enced by the previously well-described beneficial effects of steroids
in spinal cord injury patients. Their conviction that steroids were
likely to be beneficial led the authors to a study design mandating
postoperative steroid administration to all patients who showed
signs of postoperative CN dysfunction. Since all patients with
postoperative CN dysfunction were treated with steroids, theinfluence of postoperative steroids on recovery rate or in convert-
ing potentially permanent dysfunction to temporary dysfunction
cannot be determined. Perhaps a better design would have in-
cluded a secondary randomization of those with postoperative CN
dysfunction to either no additional treatment or a 1-week course of
DEX. Alternatively, the authors might now initiate a follow-up
study testing the effects of postoperative DEX on recovery in
patients with post-CEA CN dysfunction. However, given the low
incidence of CEA-associated CN dysfunction, the number of
subjects required to achieve a statistically robust study would be
prohibitive in a single institution study. Second, the optimal dose
and dosing regimen cannot be determined from this study. It is
possible that a single lower pre-incisional steroid dosemight be just
as effective as the authors’ regimen of six doses of 8 mg of DEX
(1 hour prior to CEA, 6 and 12 hours post-CEA, every 12 hours on
postoperative day #1, and once on the morning of postoperative
day #2).
This interesting and provocative study shows that the inci-
dence of CEA-associated CNdysfunction can bemarkedly reduced
with steroid pre-treatment with no adverse effects. Confirmatory
studies elucidating the influence of postoperative steroids on the
course of CN dysfunction and establishing the most practical and
effective dosing regimen are now required.
